Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors

PURPOSE: Ridaforolimus is a non-prodrug mTOR inhibitor. The safety, pharmacokinetics (PK), and antitumor activity of oral ridaforolimus were assessed in Japanese patients with refractory solid tumors. METHODS: Ridaforolimus (20 or 40 mg) was administered as a single dose on Day 1, followed by once d...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Seki, Yoshitaka, Yamamoto, Noboru, Tamura, Yosuke, Goto, Yasushi, Shibata, Takashi, Tanioka, Maki, Asahina, Hajime, Nokihara, Hiroshi, Yamada, Yasuhide, Shimamoto, Takashi, Noguchi, Kazuo, Tamura, Tomohide
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer-Verlag 2011
נושאים:
Clinical Trial Report
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3313018/
https://ncbi.nlm.nih.gov/pubmed/22143378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-011-1788-4
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים